A preclinical programme on one rare liver disease, up to 12 Saudi scientists in training, and no therapy yet. What rare disease and biotech teams should take from it.
AstraZeneca says it is moving the first phase of its CRISPR gene-editing research into Saudi Arabia, working with the King Abdullah International Medical Research Center (KAIMRC) in Riyadh. The first target is a rare inherited liver-metabolism disorder called argininosuccinate lyase deficiency, usually shortened to ASLD. The programme includes hands-on training and technology transfer for up to 12 Saudi scientists.
That is a short summary of a story that is easy to over-read. Headlines about "gene editing coming to Saudi Arabia" can sound like a treatment is close. It is not. What has been disclosed is a preclinical research programme and a capability-building plan. There is no clinical trial, no approved therapy, no disclosed budget and no announced timeline for a first study in patients.
This article sets out what is confirmed, where each fact comes from, what the programme is likely to mean for the Saudi rare disease and biotech landscape, and what teams in the region should research now. I have kept to the public record and marked clearly where it stops.
A note on sources and dates. Dawaa News MENA published its Arabic report on 8 November 2026. That report follows an interview with AstraZeneca's head in Saudi Arabia, Hatem Werdany, published by Asharq Al-Awsat on 5 November 2026. The programme itself was presented earlier, at the fourth Riyadh Global Medical Biotechnology Summit (RGMBS), held on 14 to 16 September 2026 at the Sofitel Riyadh Hotel and Convention Centre. The summit's own LinkedIn page and Werdany's LinkedIn post carry the first public descriptions I could find. So the news is not new on 8 November. The 8 November coverage is a fresh explanation of earlier disclosures.
What was announced
Four points are consistent across Asharq Al-Awsat, Dawaa News and AstraZeneca's own LinkedIn post.
First, the collaboration. AstraZeneca is working with KAIMRC to transfer the initial phase of its CRISPR gene-editing research to Saudi Arabia. KAIMRC is part of the Ministry of National Guard Health Affairs (MNGHA). Werdany thanked both bodies in his post.
Second, the target. The first research programme focuses on ASLD, a rare genetic disease. In Asharq Al-Awsat's account, the early work uses a cell model of the disease and AstraZeneca's gene-editing platform.
Third, the people. Hands-on training and technology transfer for up to 12 Saudi scientists have, according to Werdany, already begun. Asharq Al-Awsat adds that the first group of about 12 is a starting point that can be widened as the collaboration develops.
Fourth, the exposure. Participating scientists can gain training and work opportunities at AstraZeneca's Discovery Centre in Cambridge in the United Kingdom and at its global R&D site in Gothenburg, Sweden. They can also take part in international scientific forums, including the ELRIG drug discovery conference.
Two details matter for accuracy. The figure is "up to 12", not "12 trained". And the work is described as early-stage research, not a therapy in development for patients.
What the summit session added
The official RGMBS LinkedIn page published a recap of a Day 1 session called the KAIMRC Gene Therapy Localization Journey. It features three speakers: Sausan Alfaris of KAIMRC, Marcello Maresca of AstraZeneca and Seng H. Cheng of Alexion, AstraZeneca Rare Disease. The recap adds several details that the news reports do not.
The partnership, it says, has moved from programme approval to established preclinical models. Hit-finding is complete and optimisation is under way. ASLD was chosen as the first target because it is a single-gene disorder with a clear treatment gap, on a roadmap designed so that KAIMRC can eventually lead independently.
On the science, the recap says Maresca presented a liver-targeted lipid nanoparticle approach that repairs the most common disease-causing ASL variant. It reports 41 to 44 percent gene repair and up to 98 percent correct isoform in preclinical models. I have treated these numbers with caution for three reasons. They come from a summit organiser's summary of a talk, not from a peer-reviewed paper or a company release. They describe laboratory and animal-model results, which often do not carry over directly to people. And I could not find a paper or abstract giving the underlying data. They are reported here as what was said at the summit, not as established results.
The same recap records a candid panel. Asked which single advance would bring gene editing to more patients, Maresca pointed to delivery, meaning better tools to reach organs beyond the liver. Cheng argued that affordability must be built in from the start, through scalable manufacturing and adaptive regulation. Alfaris described the effort as a platform rather than a single project, built to be redeployed against the next disease and the one after that.
There is one gap between sources worth noting. Asharq Al-Awsat and Dawaa News describe the early work as a cell model. The summit recap refers to preclinical models in the plural and to a lipid nanoparticle approach, which suggests the work has moved beyond a simple cell line. Both can be true at different points in time. The public record does not let me say exactly which stage the programme is at today.
The disease: what ASLD is
ASLD is also called argininosuccinic aciduria. MedlinePlus Genetics, from the US National Library of Medicine, describes it as an inherited disorder in which ammonia accumulates in the blood. Ammonia is made when proteins are broken down and is toxic at high levels. The nervous system is especially sensitive to it.
The cause is a fault in the ASL gene, which makes an enzyme needed for the fourth step of the urea cycle. The urea cycle takes place in liver cells and turns excess nitrogen into urea, which leaves the body in urine. When the enzyme is dysfunctional or missing, nitrogen builds up as ammonia. The condition is inherited in an autosomal recessive pattern, which means a child must receive a faulty copy of the gene from each parent.
According to MedlinePlus, it usually becomes evident in the first few days of life, with symptoms such as lethargy, poor feeding and breathing or temperature problems. Some babies have seizures or go into a coma. Later complications can include developmental delay and intellectual disability, and also progressive liver damage, high blood pressure, skin lesions and brittle hair. A milder form exists, where ammonia rises only during illness or stress. MedlinePlus puts frequency at approximately 1 in 70,000 to 218,000 newborns, and notes that most cases are found shortly after birth by newborn screening.
Two caveats follow. That frequency is a general estimate, not a Saudi figure. I could not find a published Saudi prevalence for ASLD. And a rare disease with a small patient count raises a hard commercial question that any developer will face, which I come back to below.
Why AstraZeneca and KAIMRC chose a rare disease
Werdany told Asharq Al-Awsat that rare diseases are a health priority in Saudi Arabia and that gene editing may be able to address the genetic causes of some of them. A LinkedIn commenter on Werdany's post went further and linked the choice to Saudi Arabia's consanguinity rate and its local disease burden in rare metabolic conditions. That was one person's comment, not a statement from AstraZeneca or KAIMRC, and I have not used it as a fact.
From a research design perspective, a single-gene liver disorder is a sensible first target. Maresca's panel comment that the next advance is reaching organs beyond the liver implies that the liver is where delivery works best today. A defined genetic cause gives a clear thing to correct and a clear way to measure whether the correction worked.
The choice also fits the structure of the partnership. KAIMRC brings genomics and biobank expertise and knowledge of local health priorities, according to Asharq Al-Awsat. AstraZeneca brings its global R&D network, which spans small molecules, antibodies and cell therapy as well as genome engineering.
How this partnership got here
The programme did not start in September. On 22 December 2025, Dawaa News reported a visit by a Saudi delegation to AstraZeneca's Discovery Centre in Cambridge. The delegation was led by Bandar Alknawy, who is Chief Executive of Health Affairs at the Ministry of National Guard and CEO of KAIMRC. The aim was to discuss cooperation on a gene editing therapy programme.
At that time, the sides spoke of working groups to set a timetable and roadmap. The RGMBS recap in September described a programme that had moved on to preclinical models and hit-finding. So the public timeline runs from a roadmap discussion in December 2025 to a research programme with early results in September 2026, and then to explanatory coverage in November 2026.
It is still early-stage work. Nothing in the public record suggests a clinical trial in Saudi Arabia is imminent, and Dawaa News itself states that no confirmed date has been given for a first clinical study.
AstraZeneca's footprint in Saudi Arabia
Werdany gave Asharq Al-Awsat the following picture of AstraZeneca's local presence. The company has operated in Saudi Arabia since the early 1980s. More than 800 Saudi patients have taken part in its clinical trials, run at about 20 sites. It employs more than 300 people in the Kingdom, about 72 percent of them Saudi, and about 40 percent of them women. He also said the company has deepened its commitment in recent years by supporting localisation ambitions, keeping medicine supply continuous and running patient support programmes.
These are company-supplied figures and I have attributed them as such. They matter because they show the logic Werdany describes: moving from taking part in clinical trials to taking part in discovery. In his words in the Asharq Al-Awsat interview, Saudi Arabia is moving from hosting and joining clinical trials to contributing to scientific discovery and the development of treatments.
What this means for the Saudi biotech and rare disease landscape
I read the programme as a signal about capability, not about a product. Four implications stand out.
1. Talent is the first deliverable. The measurable output in the near term is people. Up to 12 scientists with hands-on experience in gene editing tools, cell models and disease modelling. Both Asharq Al-Awsat and Dawaa News say success will be tracked by the depth of expertise gained, the professional networks built and the number of people trained, alongside progress in the ASLD programme itself.
2. The programme links to national policy. Werdany tied the work to Saudi Vision 2030 and the National Biotechnology Strategy. RGMBS was held under the patronage of the Crown Prince and inaugurated by the Minister of National Guard, according to the Saudi Press Agency, and the summit says it aligns with the National Biotechnology Strategy. That context matters for stakeholders: this is an area where government priorities and company programmes point the same way.
3. Manufacturing is a long-term possibility, not a plan. Asharq Al-Awsat quotes Werdany saying that building local capability to develop, and possibly manufacture, advanced therapies is a long-term opportunity both sides are exploring. Dawaa News is more explicit: the current collaboration is not an announcement of a gene therapy manufacturing facility or a transfer of commercial production to Saudi Arabia.
4. The regulatory path needs work. Werdany listed what continued progress will require. A continuing flow of scientific talent. Infrastructure to carry research from discovery into clinical development and later advanced manufacturing. Regulatory pathways for cell and gene therapies. And sustained investment in medical research. Those are his points, and they describe what has not yet been built.
The hard questions
Any sceptic would raise the following, and I think they are fair.
Will a therapy ever come from this? Nobody can say. Early editing results in the lab, even strong ones, often face difficulties in safety, delivery, durability and manufacturing before reaching patients. The programme itself is described by Dawaa News as dependent on research results and on meeting scientific, regulatory and ethical requirements.
Who pays for rare-disease gene therapy? Affordability was raised on the summit panel by Cheng himself. For very rare diseases, the number of patients is small and the cost of developing and delivering a one-time therapy can be high. Payers, including in the Gulf, have to decide how to value that. The public record does not say how the partners would approach pricing, and I have not assumed anything.
Does training 12 scientists change a country's research base? Alone, no. It is a seed. The programme's own design as a "platform" for further diseases suggests the partners know this. Whether it grows depends on whether the first cohort is expanded and on whether Saudi institutions are able to retain and use the skills.
Is the programme reproducible for other companies? It might be, but the public record does not say. The model of a global company transferring early-phase science and training into a national research centre could be copied by others. KAIMRC co-organised the summit, so it has a platform to attract such partners.
What teams should research now
If you work in rare disease, genomic medicine or biotech in Saudi Arabia, the programme is not a reason to rewrite your forecast. It is a reason to learn earlier than usual how the ecosystem is forming. Here is where I would start.
1. Map the clinical and referral landscape for rare metabolic disease. Which centres diagnose and manage urea cycle disorders and similar conditions? How are newborn screening results acted upon? Which specialists, such as metabolic physicians, paediatric hepatologists and geneticists, are involved? Our rare disease market research in Saudi Arabia work starts here.
2. Test physician awareness and attitudes toward gene-editing therapies. What do Saudi specialists know about the technology, and what would they need to see before referring a patient to a trial? Specialist interviews are the right method. They reveal practical concerns about delivery, follow-up and long-term monitoring that survey data alone will miss.
3. Understand the regulatory pathway. The Saudi Food and Drug Authority sets requirements for orphan drugs and for advanced therapies. Our guide to rare disease and orphan drug regulation in Saudi Arabia and our SFDA registration guide set out the basics. For gene and cell therapies, early dialogue with the regulator is likely to matter.
4. Learn from adjacent advanced therapies. Saudi Arabia is already building experience with other complex treatments. Our CAR-T research in Saudi Arabia article looks at how centres, payers and physicians approach a high-cost, one-time cell therapy. Many of the same questions will apply to gene editing.
5. Understand value and payer thinking early. A health technology assessment dossier for a rare-disease therapy has specific demands. See our HTA dossier guide for Saudi Arabia. Interview payers and hospital committees about how they would weigh a high-cost therapy for a very small population.
6. Track the patient and family perspective. Rare disease patients and caregivers hold knowledge that no registry will capture: how long diagnosis took, which services they could reach, and what they would want from a trial. Research with families needs care, consent and sensitivity, and it should be designed with clinicians.
What to watch next
- Peer-reviewed data. Whether AstraZeneca and KAIMRC publish or present the preclinical results behind the 41 to 44 percent figure.
- Cohort expansion. Whether the group of up to 12 scientists is widened, and what roles they take on.
- Next targets. Whether the platform is applied to a second disease, as Alfaris suggested it could be.
- Regulatory signals. Any SFDA guidance or pathway announcements for cell and gene therapy trials.
- Other partners. Whether further global companies announce research programmes with KAIMRC or other Saudi centres. The summit also reported a KAIMRC and Thermo Fisher Scientific centre of excellence in genomics and proteomics, though I have only seen that in a LinkedIn reshare by a summit page and a sector network.
How BioNixus helps
BioNixus has run healthcare and B2B market research since 2012, with 118 clients in 48 countries. Our physician network is 82,000+ physicians globally and about 3,200 in the Middle East. Mohammad Alsaadany, our AMEA Director, leads our work across APAC, the Middle East and Africa. We work from our Americas office and global HQ in the USA, our Europe office in the UK, our AMEA office in Cairo and our KSA partner office in Al Khobar.
For rare disease, genomic medicine and biotech teams in Saudi Arabia and the wider Middle East, we run:
- Specialist physician research with metabolic physicians, geneticists, paediatric specialists and hepatologists, through physician insights interviews and surveys.
- Payer and access research that tests how stakeholders would weigh a high-cost therapy for a small population.
- Regulatory and market access support that connects study findings to your SFDA and HTA plans.
- Ecosystem mapping that identifies centres, researchers and partners across the Kingdom.
Our Saudi Arabia healthcare market research team can scope a study to your questions. Visit bionixus.com to see our approach.
Plan your Saudi rare disease and biotech research with BioNixus
If your team needs to understand how Saudi specialists, payers and regulators will approach advanced therapies, talk to us. BioNixus combines a physician network of 82,000+ physicians globally and about 3,200 in the Middle East with local expertise from our AMEA office in Cairo and our KSA partner office in Al Khobar. Start a conversation at bionixus.com/contact.
